StockNews.AI
PEPG
StockNews.AI
40 days

PepGen Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPG

1. PepGen faces class action due to misleading statements about PGN-EDO51. 2. Allegations claim PGN-EDO51 was less effective than claimed. 3. CONNECT2 study allegedly lacked FDA approval safety and efficacy. 4. Potential halt of CONNECT2 study could undermine PGN-EDO51's prospects. 5. Shareholders can register for class action recovery by August 8, 2025.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Historical cases show that allegations of misleading statements often lead to significant stock price declines, especially when regulatory approvals are questioned. For instance, similar lawsuits have resulted in crashes for clinical stage biotech companies like Akorn Inc. and CytRx Corporation.

How important is it?

The presence of a class action lawsuit related to misleading product efficacy and safety directly threatens investor confidence, likely leading to heightened scrutiny and distrust around PEPG's management and forecasts.

Why Short Term?

As the class action progresses and more information surfaces, immediate investor reactions to negative news will likely impact PEPG's stock. Short-term volatility might increase as the deadline for registration approaches.

Related Companies

AKRXCYTRVRTX
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG). Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=156049&from=3 CLASS PERIOD: March 7, 2024 to March 3, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s lead product candidate, PGN-EDO51, was less effective and safe than defendants had led investors to believe; (ii) phase two, CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration (“FDA”) approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51’s clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times. DEADLINE: August 8, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=156049&from=3 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of PEPG during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 8, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.comPhone: (646) 453-8903

Related News